Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.
You see forecasting of therapeutic submarkets to 2022, finding potential revenues:
• Hepatitis B
• Hepatitis C.
You also find revenue forecasting of product classes to 2022:
• Oral antivirals
How will 10 leading products - including Baraclude, Pegasys, Incivek and PegIntron - perform from 2012? Our investigation gives you business research and analysis with sales forecasts for leading brands. You discover their growth potential.
The market is changing. You find discussions of treatments in development, by phase and indication. In the study you also see predictions of launch times for product candidates.
Market value for 2012 and prospects for the future
What does the future hold? The pharma industry will improve treatments for hepatitis and increase revenues there from 2012 to 2022. In particular, the R&D pipeline for hepatitis C is strong and promising. World revenues will grow to $8.7bn in 2012, our analysis shows.
We estimate that more than 15 new therapies will reach the market by 2016. Almost all of those pipeline candidates are oral direct-acting antivirals. You see opportunities there.
What about companies? Our work discusses Roche, GSK, Bristol-Myers Squibb, Merck, Novartis and many other pharmaceutical manufacturers, analysing prospects of the industry.
The main goal for hepatitis C therapy is all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected towards the middle of this decade.
High rates of efficacy and barriers to resistance in leading treatments mean the world hepatitis B treatment market will grow strongly to 2016, our report predicts. Generic competition will become noticeable afterwards, however.
Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging national markets, and increased virus screening will also stimulate the world market from 2012 onwards, we find.
Many commercial opportunities for hepatitis-treating agents exist, with high revenues possible to 2022. Our report shows you and explains.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 80 tables, 64 charts and a research interview.
Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover projected revenue trends of 10 leading brands to 2022
• See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
• Assess 7 leading companies, and other players, discovering activities and outlooks
• Review R&D pipelines, seeing trends by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from the sector, seeing an interview with an external authority.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
American University in Cairo
Anadys Pharmaceuticals (now part of Roche)
Anhui Biochem Bio-Pharmaceutical
Beijing Key Yuan Xinhai Pharmaceutical
Beijing Wantai Biological Pharmacy Enterprise
BioPhausia (now part of Medivir)
Biotechnology Enterprise Management
Bristol-Myers Squibb (BMS)
Centers for Disease Control and Prevention (CDC) [US]
China NT Pharma Group
Chinese Foundation for Hepatitis Prevention and Control (CFHPC)
Chiron (now part of Novartis)
Chugai Pharmaceutical (part of Roche)
Corvas International (now part of Dendreon)
CPP Investment Board
Drug Controller General of India (DCGI)
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
European Association for the Study of the Liver (EASL)
European Commission (EC)
European Liver Patients Association (ELPA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Genelabs Technologies (now part of GSK)
Hainan Zhonghe Pharmaceutical
Health Protection Agency (HPA) [UK]
Imperial College London
Inhibitex (now part of BMS)
Institut de Veille Sanitaire (InVS) [France]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
Institut National de la Santé et de la Recherche Médicale (INSERM) [France]
Janssen Pharmaceutica (a subsidiary of J&J)
Kun Run Biotechnology
LG Life Sciences
Maxwell Biotech Venture Fund
Merck & Co.
Ministry of Health [China]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Pharmasset (now part of Gilead)
Reliance Life Sciences
Rhein Biotech (now part of Dynavax Technologies)
Schering-Plough (now part of Merck & Co)
Scottish Medicines Consortium (SMC)
State Food and Drug Administration (SFDA) [China]
The Vaccine Fund
Tibotec Pharmaceuticals (a subsidiary of Janssen Pharmaceutica)
University of Alberta
University of Heidelberg
Valeant Pharmaceuticals International
ViroChem Pharma (now part of Vertex)
Welsh School of Pharmacy (Cardiff University)
World Health Organization (WHO)
World Hepatitis Alliance
Xiamen Innovax Biotech
ZymoGenetics (now part of BMS)